Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kyle Gano also recently made the following trade(s):

• On Tuesday, November 4th, Kyle Gano sold 300 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00.

Neurocrine Biosciences Trading Up 1.6%

Shares of NBIX opened at $134.54 on Wednesday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $160.18. The firm has a market capitalization of $13.41 billion, a P/E ratio of 32.19, a P/E/G ratio of 0.65 and a beta of 0.28. The firm has a 50-day moving average price of $144.15 and a 200 day moving average price of $140.11.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million for the quarter, compared to the consensus estimate of $746.61 million. During the same period in the previous year, the firm earned $1.81 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 27.8% compared to the same quarter last year. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several hedge funds have recently bought and sold shares of the company. BAM Wealth Management LLC grew its holdings in shares of Neurocrine Biosciences by 13.1% in the fourth quarter. BAM Wealth Management LLC now owns 2,343 shares of the company’s stock valued at $332,000 after purchasing an additional 271 shares in the last quarter. Signaturefd LLC boosted its position in Neurocrine Biosciences by 4.5% in the 4th quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock valued at $273,000 after buying an additional 83 shares during the period. Savvy Advisors Inc. boosted its position in Neurocrine Biosciences by 37.7% in the 4th quarter. Savvy Advisors Inc. now owns 2,374 shares of the company’s stock valued at $337,000 after buying an additional 650 shares during the period. Whalen Wealth Management Inc. grew its stake in shares of Neurocrine Biosciences by 14.9% in the fourth quarter. Whalen Wealth Management Inc. now owns 5,125 shares of the company’s stock worth $727,000 after acquiring an additional 663 shares in the last quarter. Finally, Perpetual Ltd purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $388,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Citigroup increased their price objective on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday. Needham & Company LLC boosted their price objective on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Truist Financial decreased their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.10.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.